Remdesivir: a pendulum in a pandemic

BMJ. 2020 Nov 24:371:m4560. doi: 10.1136/bmj.m4560.

Authors

Ilan S Schwartz¹, Emily L Heil², Erin K McCreary³

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
² Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
³ Department of Medicine, Division of Infectious Diseases, UPMC Health System and the University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA mccrearye3@upmc.edu.

PMID: 33234523
DOI: 10.1136/bmj.m4560

No abstract available

Publication types

Editorial

MeSH terms

Adenosine Monophosphate / analogs & derivatives*
Adenosine Monophosphate / therapeutic use
Alanine / analogs & derivatives*
Alanine / therapeutic use
Antiviral Agents / therapeutic use*
COVID-19 Drug Treatment*
Humans
Randomized Controlled Trials as Topic
SARS-CoV-2 / drug effects*
Treatment Outcome

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine